Introduction
Cancer is rarely suppressed by the host immune response since tumour cells acquire immune tolerance. The failure of an anti-cancer immune response may be due to a specific subpopulation of regulatory T cells (Treg) [
1]. Treg down-regulate the activation and expansion of self-reactive lymphocytes [
2], and are crucial for the repression of autoimmune disorders and transplant rejection [
3,
4]. Although the role of Treg in cancer has not been fully elucidated, these cells are likely to be responsible for maintaining the self-tolerance that may hinder the generation and activity of anti-tumour reactive T cells [
2]. This is supported by observations that depletion of Treg [
1,
5,
6] and transforming growth β secreted by Treg [
7,
8] correlate with an enhanced immune response to cancer vaccines. Recently we and others have demonstrated that tumour infiltration by Treg, independent of other lymphoid populations, is associated with a reduced survival in breast and other cancers [
9‐
13].
Breast cancers are heterogeneous and one recognised subgroup, basal-like breast cancers, derive their name from the characteristic expression of basal cytokeratins (CK) 5, 14 and 17 [
14,
15]. These tumours account for up to 15% of all invasive breast cancers [
16], and are frequently observed in patients with BRCA1-related cancers [
17]. Despite the presence of a dense lymphoid infiltrate on histology, which is suggestive of an anti-tumour immune response [
17], they are associated with a more aggressive clinical course characterised by shorter survival and a higher risk of metastasis [
17]. We hypothesize that this is due, in part, to suppression of the immune response by Treg.
In non-neoplastic tissues, Treg are recruited by chemokines such as CXCL12 secreted by bone marrow, lymph node and inflammatory cells [
18], a mechanism that is replicated in tumours through chemokine secretion by neoplastic cells [
18]. Thus CXCL12, which binds to its cognate receptor CXCR4 expressed by Treg, has been implicated in the recruitment of Treg in a number of tumours including ovarian cancer [
19], adenocarcinoma of the lung [
20], malignant mesothelioma [
21], and the myelodysplastic syndromes [
22]. CXCR4 expression is induced under hypoxic stress via activation of the HIF pathway in a number of cell types including B lymphocytes [
23], tumour associated monocytes and endothelial cells [
24], microglia [
25], multipotent stem cells, stromal cells [
26,
27], cardiac monocytes and fibroblasts [
28]. Furthermore, the HIF pathway enhances the immunosuppressive activity of Treg by promoting the expression of their lineage transcriptional regulator FOXP3 [
29]. Given the role of hypoxia in T cell activation [
30,
31], and also specifically in Treg [
29], we hypothesised that Treg recruitment is dependent on both CXCL12 production by tumour cells and hypoxia-induced CXCR4 expression in Treg. We further hypothesize that since basal-like tumours have an enhanced hypoxic drive [
32] this mechanism may be prominent in basal-like breast cancer.
We, therefore, investigated CXCR4 expression in Treg, together with the expression of CA9 and CXCL12 in basal-like and other subtypes of breast cancers. The significance of this project lies in the rational design of tumour vaccine approaches or blocking antibodies [
33]. Therapies targeting Treg are entering clinical trials [
34,
35]; therefore, it is important to quantify Treg numbers and to assess factors that may affect their recruitment to the tumour microenvironment. Thus, should findings suggest that hypoxia driven recruitment of Treg via the CXCL12/CXCR4 axis plays a significant role in basal-like tumours, therapies targeting CXCL12/CXCR4 and HIF pathways, in addition to targeting Treg may be beneficial for this subset of breast cancers that are less likely to respond to conventional therapies.
Discussion
In view of the association among basal-like breast cancer, its dense lymphoid infiltrate and aggressive behaviour, we hypothesized that basal-like tumours evade the anti-tumour immune response via the recruitment of Treg. In our study, basal-like tumours were associated with high Treg and a four-fold increase in the median number of Treg compared with luminal tumours. Furthermore, this association was independent of tumour size and grade and conferred a poor survival in this subtype. These results are in keeping with our previous study in an independent cohort where Treg infiltration correlated with high tumour grade, HER2 positivity, ER negativity and poor survival [
11]. and with Bohling
et al. [
45] in their comparison of 26 grade 3 triple negative cancers with 71 non-grade 3 non-triple negative cancers.
Although high Treg were also associated with an adverse outcome in luminal cancers in our cohort of HER positive patients, who were not treated with trastuzumab, accumulation of Treg did not correlate with survival. Although the reason for the latter result is unclear, one potential explanation is Treg immune suppression may have no effect on an immune response which is ineffective in the first instance. This is supported by studies where the anti-tumour immune response against HER2 cancers could be boosted by an infusion of HER2 specific T cells [
46].
A number of chemokines have been implicated in the recruitment of Treg in non-neoplastic tissues [
18]. Recent studies on breast cancers have shown that two of these chemokines, CCL20 [
13] and CCL22 [
12], may recruit Treg that express the corresponding chemokine receptors CCR6 and CCR4. Our results demonstrate CXCL12 derived from tumour cells may also be involved in Treg recruitment. While tumour CXCL12 expression correlated with tumour Treg recruitment, this did not appear to account for the increased number of Treg observed in basal-like cancers. Indeed, a lower proportion of basal-like cancers expressed CXCL12 (59%) compared with luminal cancers (74%). Our findings suggest preferential Treg recruitment in basal-like cancers may be in part explained by CXCR4 up-regulation in Treg. This is supported by
in vitro cell migration assays where induction of CXCR4 expression in Treg resulted in their migration towards a CXCL12 gradient [
19,
20], and could be terminated by incubation with an anti-CXCR4 antibody [
19]. Preferential accumulation of CXCR4 positive Treg, and its correlation with tumour CXCL12 expression, has also been previously demonstrated in adenocarcinomas of the lung [
20] and malignant mesothelioma [
21].
CXCL12 is a chemokine which exclusively binds to the CXCR4 receptor. It is also the only ligand for the CXCR4 receptor [
47]. CXCR4 expression is induced by hypoxia [
24,
48]. Using CA9 as a surrogate marker of hypoxia [
42‐
44], we demonstrated that hypoxia is associated with the accumulation of Treg and also the subset of CXCR4 positive Treg in breast cancer. This, together with our previous finding that hypoxia is a feature of basal-like breast cancers, suggests increased Treg infiltration in basal-like cancers may be in part due to hypoxia-induced up-regulation of CXCR4 in Treg. The correlations identified in our study are mechanistically supported by
in vitro studies, where T cells incubated under hypoxic conditions show a time-dependent increase in HIF-1α [
29‐
31]. Furthermore, the link between HIF-1α and CXCR4 expression is supported by a number of findings [
24] including: a) reduction of CXCR4 in VHL mutated cell lines [
24], b) increased IL-2 receptor (also implicated in CXCR4 up-regulation), and reduced CCR6 (another receptor implicated in Treg recruitment) expression in T cells stimulated by hypoxia [
31], c) HIF-1α recruitment to the
CXCR4 promoter in the hypoxic state [
24] and d) hypoxia-induced expression of CXCR4, but not CCR6, CCR7, CXCR3 or CXCR5 [
23]. HIF-1α may also induce CXCR4 expression indirectly by up-regulating the expression of FOXP3, which binds regulatory sequences upstream of the transcriptional start site of CXCR4 resulting in CXCR4 over-expression [
49]. Furthermore, hypoxia increases the potency of Treg in suppressing the proliferation of effector CD4+ T cells [
29,
50]. There are likely also to be other cytokines regulating T cell recruitment and a comprehensive analysis of hypoxia-induced cytokines and their cognate receptors would be valuable, but need to be directed by detailed analysis of pathways regulated in these cells
in vitro. The effect of hypoxia on Treg appears to be independent of other factors expressed by the basal subtype as the correlation between hypoxia and Treg was re-duplicated in non-basal tumours.
Loss of CXCL12 expression, in this study and in previous studies [
51], is associated with a poor prognosis. Tumour cells with reduced CXCL12 in their immediate microenvironment may be at an advantage to receive endocrine CXCL12 signals, promoting their migration towards ectopic sources of the CXCR4 ligand. This is supported by mouse models where metastasis of tumour xenografts to the lung may be inhibited by endogenous CXCL12 expression in the xenografted tumour [
52]. While CXCL12 expression is associated with a favourable prognosis in an analysis of all breast cancers, there may be significant heterogeneity in the impact of CXCL12 on tumour behaviour between subtypes. For example, while CXCL12 is associated with a good prognosis in non-basal breast cancers (log rank test
P = 0.002), but no such correlation is seen for basal cancers (
P = 0.688). In the setting of profound hypoxia and CXCR4 up-regulation in Treg, as occurs in basal-like breast cancer, CXCL12 may have a negative consequence of enhancing Treg recruitment and suppressing the anti-tumour immune response. Although CXCL12 may also recruit other T cell subsets, it appears to preferentially recruit Treg, rather than CD8 cytotoxic or CD4 helper T cells [
20,
53].
Conclusions
These findings have important implications, as they suggest basal-like cancers, which are traditionally resistant to targeted therapies and may potentially respond to immunotherapy targeting Treg. Furthermore, Treg recruitment by CXCL12/CXCR4 in these cancers may potentially be modulated by treatment directed against the HIF-1α pathway. Thus there is an opportunity for clinical trials based on robust reagents directed against Treg, or antibodies blocking CXCR4, to stratify patients for anti-HIF therapies. Indeed, many potent HIF-1 inhibitors are FDA-approved cancer treatment agents including anthracyclines and topotecan enabling clinical trials to test their effectiveness [
54,
55]. Side effects should be minimal since these agents are chronically administered at low dose to derive their anti-HIF activity. There are some data to suggest that the anthracycline analogue, mitoxanthrone, lowers the number of Treg in tumours [
56] and such agents may be combined with multiple immunotherapy strategies that also reduce Treg numbers, enabling an improved effector cell response to a vaccine.
Acknowledgements
This study was supported in part by the Victorian Breast Cancer Research Consortium, the Victorian Cancer Biobank, Cancer Council Victoria, Cancer Institute of New South Wales, the Australian Cancer Research Foundation, the Petre Foundation, the National Health and Medical Research Council (Project grant 400207 to HX; Project Grants: 535903 and 535947 to EM and RS) and the RT Hall Trust, Australia.
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
SF and MY conceived the experiments. Experiments were carried out by MY, NJ and DB. MY, SF, EM, SO, CM, GB, AH, AB and RS were involved in the collection and analysis of data. All authors were involved in writing the paper and had final approval of the submitted version.